Links between DNA double strand break repair and breast cancer: Accumulating evidence from both familial and nonfamilial cases

Cancer Letters

Volumn 248, Issue 1, 2007, Pages 1-17

  Ralhan, Ranju ^a   Kaur, Jatinder ^a   Kreienberg, Rolf ^b   Wiesmüller, Lisa ^b  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

Brca; Breast Cancer; Double strand break; Recombination; Repair

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CHECKPOINT KINASE 2; DNA; PROTEIN P53; RAD50 PROTEIN; RAD51 PROTEIN; RAD52 PROTEIN; RAD54 PROTEIN; SINGLE STRANDED DNA;

ATAXIA TELANGIECTASIA; ATM GENE; BREAST CANCER; CANCER RISK; DISEASE PREDISPOSITION; DNA DAMAGE; DNA REPAIR; DNA STRAND BREAKAGE; FAMILIAL CANCER; GENETIC RECOMBINATION; GENETIC SUSCEPTIBILITY; GENOMIC INSTABILITY; HUMAN; ONCOGENE; OVARY CANCER; PRIORITY JOURNAL; SHORT SURVEY; TUMOR SUPPRESSOR GENE;

EID: 33847271255     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2006.06.004     Document Type: Review

References (140)

1. Parkin D.M. International variation. Oncogene 23 (2004) 6329-6340
2. Narod S.A., and Foulkes W.D. BRCA1 and BRCA2: 1994 and beyond. Nat. Rev. Cancer 4 (2004) 665-676
3. Pharoah P.D., Antoniou A., Bobrow M., Zimmern R.L., Easton D.F., and Ponder B.A. Polygenic susceptibility to breast cancer and implications for prevention. Nat. Genet. 31 (2002) 33-36
4. Parshad R., and Sanford K.K. Radiation-induced chromatid breaks and deficient DNA repair in cancer predisposition. Crit. Rev. Oncol. Hematol. 37 (2001) 87-96
5. Thompson L.H., and Schild D. Recombinational DNA repair and human disease. Mutat. Res. 509 (2002) 49-78
6. Speit G., and Trenz K. Chromosomal mutagen sensitivity associated with mutations in BRCA genes. Cytogenet. Genome Res. 104 (2004) 325-332
7. Turner N., Tutt A., and Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat. Rev. Cancer 4 (2004) 814-819
8. Rothkamm K., Kruger I., Thompson L.H., and Lobrich M. Pathways of DNA double-strand break repair during the mammalian cell cycle. Mol. Cell. Biol. 23 (2003) 5706-5715
9. Valerie K., and Povirk L.F. Regulation and mechanisms of mammalian double-strand break repair. Oncogene 22 (2003) 5792-5812
10. Stracker T.H., Theunissen J.W., Morales M., and Petrini J.H. The Mre11 complex and the metabolism of chromosome breaks: the importance of communicating and holding things together. DNA Repair (Amst.) 3 (2004) 845-854
11. Baumann P., Benson F.E., and West S.C. Human Rad51 protein promotes ATP-dependent homologous pairing and strand transfer reactions in vitro. Cell 87 (1996) 757-766
12. Shim K.S., Schmutte C., Tombline G., Heinen C.D., and Fishel R. hXRCC2 enhances ADP/ATP processing and strand exchange by hRAD51. J. Biol. Chem. 279 (2004) 30385-30394
13. Thacker J. The RAD51 gene family, genetic instability and cancer. Cancer Lett. 219 (2005) 125-135
14. Sugiyama T., and Kowalczykowski S.C. Rad52 protein associates with replication protein A (RPA)-single-stranded DNA to accelerate Rad51-mediated displacement of RPA and presynaptic complex formation. J. Biol. Chem. 277 (2002) 31663-31672
15. Buck D., Malivert L., de Chasseval R., Barraud A., Fondaneche M.C., Sanal O., Plebani A., Stephan J.L., Hufnagel M., le Deist F., Fischer A., Durandy A., de Villartay J.P., and Revy P. Cernunnos, a novel nonhomologous end-joining factor, is mutated in human immunodeficiency with microcephaly. Cell 124 (2006) 287-299
16. Ahnesorg P., Smith P., and Jackson S.P. XLF interacts with the XRCC4-DNA ligase IV complex to promote DNA nonhomologous end-joining. Cell 124 (2006) 301-313
17. Sekiguchi J.M., and Ferguson D.O. DNA double-strand break repair: a relentless hunt uncovers new prey. Cell 124 (2006) 260-262
18. Riballo E., Kuhne M., Rief N., Doherty A., Smith G.C., Recio M.J., Reis C., Dahm K., Fricke A., Krempler A., Parker A.R., Jackson S.P., Gennery A., Jeggo P.A., and Lobrich M. A pathway of double-strand break rejoining dependent upon ATM, Artemis, and proteins locating to gamma-H2AX foci. Mol. Cell 16 (2004) 715-724
19. Jasin M. Homologous repair of DNA damage and tumorigenesis: the BRCA connection. Oncogene 21 (2002) 8981-8993
20. Yoshida K., and Miki Y. Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci. 95 (2004) 866-871
21. Morrison C., Sonoda E., Takao N., Shinohara A., Yamamoto K., and Takeda S. The controlling role of ATM in homologous recombinational repair of DNA damage. EMBO J. 19 (2000) 463-471
22. Golding S.E., Rosenberg E., Khalil A., McEwen A., Holmes M., Neill S., Povirk L.F., and Valerie K. Double strand break repair by homologous recombination is regulated by cell cycle-independent signaling via ATM in human glioma cells. J. Biol. Chem. 279 (2004) 15402-15410
23. Bertrand P., Saintigny Y., and Lopez B.S. p53's double life: transactivation-independent repression of homologous recombination. Trends Genet. 20 (2004) 235-243
24. Gatz S.A., and Wiesmuller L. p53 in recombination and repair. Cell Death Differ. 13 (2006) 1003-1016
25. Patel R.K., Trivedi A.H., Arora D.C., Bhatavdekar J.M., and Patel D.D. DNA repair proficiency in breast cancer patients sand their first-degree relatives. Int. J. Cancer 73 (1997) 20-24
26. Varga D., Michel I., Patino-Garcia B., Paiss T., Vogel W., and Maier C. Radiosensitivity detected by the micronucleus test is not generally increased in sporadic prostate cancer patients. Cytogenet. Genome Res. 111 (2005) 41-45
27. Shen C.Y., Yu J.C., Lo Y.L., Kuo C.H., Yue C.T., Jou Y.S., Huang C.S., Lung J.C., and Wu C.W. Genome-wide search for loss of heterozygosity using laser capture microdissected tissue of breast carcinoma: an implication for mutator phenotype and breast cancer pathogenesis. Cancer Res. 60 (2000) 3884-3892
28. DePinho R.A., and Polyak K. Cancer chromosomes in crisis. Nat. Genet. 36 (2004) 932-934
29. Cavalieri E.L., Stack D.E., Devanesan P.D., Todorovic R., Dwivedy I., Higginbotham S., Johansson S.L., Patil K.D., Gross M.L., Gooden J.K., Ramanathan R., Cerny R.L., and Rogan E.G. Molecular origin of cancer: catechol estrogen-3,4-quinones as endogenous tumor initiators. Proc. Natl. Acad. Sci. USA 94 (1997) 10937-10942
30. Cheng T.C., Chen S.T., Huang C.S., Fu Y.P., Yu J.C., Cheng C.W., Wu P.E., and Shen C.Y. Breast cancer risk associated with genotype polymorphism of the catechol estrogen-metabolizing genes: a multigenic study on cancer susceptibility. Int. J. Cancer 113 (2005) 345-353
31. Liehr J.G. Genotoxicity of the steroidal oestrogens oestrone and oestradiol: possible mechanism of uterine and mammary cancer development. Hum. Reprod. 7 (2001) 273-281
32. Huang C.S., Chern H.D., Chang K.J., Cheng C.W., Hsu S.M., and Shen C.Y. Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility. Cancer Res. 59 (1999) 4870-4875
33. Harrison L., Hatahet Z., and Wallace S.S. In vitro repair of synthetic ionizing radiation-induced multiply damaged DNA sites. J. Mol. Biol. 290 (1999) 667-684
34. Liehr J.G. Is estradiol a genotoxic mutagenic carcinogen?. Endocr. Rev. 21 (2000) 40-54
35. Lavin M.F., Concannon P., and Gatti R.A. Eighth international workshop on ataxia-telangiectasia (ATW8). Cancer Res. 59 (1999) 3845-3849
36. Rotman G., and Shiloh Y. ATM: from gene to function. Hum. Mol. Genet. 7 (1998) 1555-1563
37. Dork T., Bendix R., Bremer M., Rades D., Klopper K., Nicke M., Skawran B., Hector A., Yamini P., Steinmann D., Weise S., Stuhrmann M., and Karstens J.H. Spectrum of ATM gene mutations in a hospital-based series of unselected breast cancer patients. Cancer Res. 61 (2001) 7608-7615
38. Swift M., Reitnauer P.J., Morrell D., and Chase C.L. Breast and other cancers in families with ataxia-telangiectasia. N. Engl. J. Med. 316 (1987) 1289-1294
39. Stankovic T., Kidd A.M., Sutcliffe A., McGuire G.M., Robinson P., Weber P., Bedenham T., Bradwell A.R., Easton D.F., Lennox G.G., Haites N., Byrd P.J., and Taylor A.M. ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer. Am. J. Hum. Genet. 62 (1998) 334-345
40. Buchholz T.A., Weil M.M., Ashorn C.L., Strom E.A., Sigurdson A., Bondy M., Chakraborty R., Cox J.D., McNeese M.D., and Story M.D. A Ser49Cys variant in the ataxia telangiectasia, mutated, gene that is more common in patients with breast carcinoma compared with population controls. Cancer 100 (2004) 1345-1351
41. Thorstenson Y.R., Roxas A., Kroiss R., Jenkins M.A., Yu K.M., Bachrich T., Muhr D., Wayne T.L., Chu G., Davis R.W., Wagner T.M., and Oefner P.J. Contributions of ATM mutations to familial breast and ovarian cancer. Cancer Res. 63 (2003) 3325-3333
42. Chenevix-Trench G., Spurdle A.B., Gatei M., Kelly H., Marsh A., Chen X., Donn K., Cummings M., Nyholt D., Jenkins M.A., Scott C., Pupo G.M., Dork T., Bendix R., Kirk J., Tucker K., McCredie M.R., Hopper J.L., Sambrook J., Mann G.J., and Khanna K.K. Dominant negative ATM mutations in breast cancer families. J. Natl. Cancer Inst. 94 (2002) 205-215
43. Gatti R.A., Tward A., and Concannon P. Cancer risk in ATM heterozygotes: a model of phenotypic and mechanistic differences between missense and truncating mutations. Mol. Genet. Metab. 68 (1999) 419-423
44. Inskip H.M., Kinlen L.J., Taylor A.M., Woods C.G., and Arlett C.F. Risk of breast cancer and other cancers in heterozygotes for ataxia-telangiectasia. Br. J. Cancer 79 (1999) 1304-1307
45. Olsen J.H., Hahnemann J.M., Borresen-Dale A.L., Brondum-Nielsen K., Hammarstrom L., Kleinerman R., Kaariainen H., Lonnqvist T., Sankila R., Seersholm N., Tretli S., Yuen J., Boice Jr. J.D., and Tucker M. Cancer in patients with ataxia-telangiectasia and in their relatives in the nordic countries. J. Natl. Cancer Inst. 93 (2001) 121-127
46. Thompson D., Antoniou A.C., Jenkins M., Marsh A., Chen X., Wayne T., Tesoriero A., Milne R., Spurdle A., Thorstenson Y., Southey M., Giles G.G., Khanna K.K., Sambrook J., Oefner P., Goldgar D., Hopper J.L., Easton D., and Chenevix-Trench G. Two ATM variants and breast cancer risk. Hum. Mutat. 25 (2005) 594-595
47. Thompson D., Duedal S., Kirner J., McGuffog L., Last J., Reiman A., Byrd P., Taylor M., and Easton D.F. Cancer risks and mortality in heterozygous ATM mutation carriers. J. Natl. Cancer Inst. 97 (2005) 813-822
48. Cavaciuti E., Lauge A., Janin N., Ossian K., Hall J., Stoppa-Lyonnet D., and Andrieu N. Cancer risk according to type and location of ATM mutation in ataxia-telangiectasia families. Genes Chromosomes Cancer 42 (2005) 1-9
49. Sanford K.K., Parshad R., Price F.M., Jones G.M., Tarone R.E., Eierman L., Hale P., and Waldmann T.A. Enhanced chromatid damage in blood lymphocytes after G2 phase × irradiation, a marker of the ataxia-telangiectasia gene. J. Natl. Cancer Inst. 82 (1990) 1050-1054
50. Bakkenist C.J., and Kastan M.B. Initiating cellular stress responses. Cell 118 (2004) 9-17
51. Kurz E.U., and Lees-Miller S.P. DNA damage-induced activation of ATM and ATM-dependent signaling pathways. DNA Repair (Amst.) 3 (2004) 889-900
52. Scott S.P., Bendix R., Chen P., Clark R., Dork T., and Lavin M.F. Missense mutations but not allelic variants alter the function of ATM by dominant interference in patients with breast cancer. Proc. Natl. Acad. Sci. USA 99 (2002) 925-930
53. Gorski B., Debniak T., Masojc B., Mierzejewski M., Medrek K., Cybulski C., Jakubowska A., Kurzawski G., Chosia M., Scott R., and Lubinski J. Germline 657del5 mutation in the NBS1 gene in breast cancer patients. Int. J. Cancer 106 (2003) 379-381
54. Steffen J., Varon R., Mosor M., Maneva G., Maurer M., Stumm M., Nowakowska D., Rubach M., Kosakowska E., Ruka W., Nowecki Z., Rutkowski P., Demkow T., Sadowska M., Bidzinski M., Gawrychowski K., and Sperling K. Increased cancer risk of heterozygotes with NBS1 germline mutations in Poland. Int. J. Cancer 111 (2004) 67-71
55. Gorski B., Cybulski C., Huzarski T., Byrski T., Gronwald J., Jakubowska A., Stawicka M., Gozdecka-Grodecka S., Szwiec M., Urbanski K., Mitus J., Marczyk E., Dziuba J., Wandzel P., Surdyka D., Haus O., Janiszewska H., Debniak T., Toloczko-Grabarek A., Medrek K., Masojc B., Mierzejewski M., Kowalska E., Narod S.A., and Lubinski J. Breast cancer predisposing alleles in Poland. Breast Cancer Res. Treat. 92 (2005) 19-24
56. Heikkinen K., Rapakko K., Karppinen S.M., Erkko H., Knuutila S., Lundan T., Mannermaa A., Borresen-Dale A.L., Borg A., Barkardottir R.B., Petrini J., and Winqvist R. RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability. Carcinogenesis (2006)
57. Kanaar R., Hoeijmakers J.H., and van Gent D.C. Molecular mechanisms of DNA double strand break repair. Trends Cell Biol. 8 (1998) 483-489
58. Venkitaraman A.R. Breast cancer genes and DNA repair. Science 286 (1999) 1100-1102
59. Chen J.J., Silver D., Cantor S., Livingston D.M., and Scully R. BRCA1, BRCA2, and Rad51 operate in a common DNA damage response pathway. Cancer Res. 59 (1999) 1752s-1756s
60. Bertwistle D., and Ashworth A. Functions of the BRCA1 and BRCA2 genes. Curr. Opin. Genet. Dev. 8 (1998) 14-20
61. Vogelstein B., Lane D., and Levine A.J. Surfing the p53 network. Nature 408 (2000) 307-310
62. Agarwal M.L., Taylor W.R., Chernov M.V., Chernova O.B., and Stark G.R. The p53 network. J. Biol. Chem. 273 (1998) 1-4
63. Stark J.M., Pierce A.J., Oh J., Pastink A., and Jasin M. Genetic steps of mammalian homologous repair with distinct mutagenic consequences. Mol. Cell. Biol. 24 (2004) 9305-9316
64. Cantor S., Drapkin R., Zhang F., Lin Y., Han J., Pamidi S., and Livingston D.M. The BRCA1-associated protein BACH1 is a DNA helicase targeted by clinically relevant inactivating mutations. Proc. Natl. Acad. Sci. USA 101 (2004) 2357-2362
65. Cantor S.B., and Andreassen P.R. Assessing the link between BACH1 and BRCA1 in the FA pathway. Cell Cycle 5 (2006)
66. Brzovic P.S., Meza J.E., King M.C., and Klevit R.E. BRCA1 RING domain cancer-predisposing mutations. Structural consequences and effects on protein-protein interactions. J. Biol. Chem. 276 (2001) 41399-41406
67. Clapperton J.A., Manke I.A., Lowery D.M., Ho T., Haire L.F., Yaffe M.B., and Smerdon S.J. Structure and mechanism of BRCA1 BRCT domain recognition of phosphorylated BACH1 with implications for cancer. Nat. Struct. Mol. Biol. 11 (2004) 512-518
68. Taniguchi T., and D'Andrea A.D. Molecular pathogenesis of Fanconi anemia: recent progress. Blood 107 (2006) 4223-4233
69. Pellegrini L., Yu D.S., Lo T., Anand S., Lee M., Blundell T.L., and Venkitaraman A.R. Insights into DNA recombination from the structure of a RAD51-BRCA2 complex. Nature 420 (2002) 287-293
70. Yang H., Jeffrey P.D., Miller J., Kinnucan E., Sun Y., Thoma N.H., Zheng N., Chen P.L., Lee W.H., and Pavletich N.P. BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure. Science 297 (2002) 1837-1848
71. Wong J.M., Ionescu D., and Ingles C.J. Interaction between BRCA2 and replication protein A is compromised by a cancer-predisposing mutation in BRCA2. Oncogene 22 (2003) 28-33
72. Kato M., Yano K., Matsuo F., Saito H., Katagiri T., Kurumizaka H., Yoshimoto M., Kasumi F., Akiyama F., Sakamoto G., Nagawa H., Nakamura Y., and Miki Y. Identification of Rad51 alteration in patients with bilateral breast cancer. J. Hum. Genet. 45 (2000) 133-137
73. Kim M.K., Zitzmann S., Westermann F., Arnold K., Brouwers S., Schwab M., and Savelyeva L. Increased rates of spontaneous sister chromatid exchange in lymphocytes of BRCA2+/- carriers of familial breast cancer clusters. Cancer Lett. 210 (2004) 85-94
74. Baldeyron C., Jacquemin E., Smith J., Jacquemont C., De Oliveira I., Gad S., Feunteun J., Stoppa-Lyonnet D., and Papadopoulo D. A single mutated BRCA1 allele leads to impaired fidelity of double strand break end-joining. Oncogene 21 (2002) 1401-1410
75. Bau D.T., Fu Y.P., Chen S.T., Cheng T.C., Yu J.C., Wu P.E., and Shen C.Y. Breast cancer risk and the DNA double-strand break end-joining capacity of nonhomologous end-joining genes are affected by BRCA1. Cancer Res. 64 (2004) 5013-5019
76. Tutt A., Bertwistle D., Valentine J., Gabriel A., Swift S., Ross G., Griffin C., Thacker J., and Ashworth A. Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences. EMBO J. 20 (2001) 4704-4716
77. Varley J.M. Germline TP53 mutations and Li-Fraumeni syndrome. Hum. Mutat. 21 (2003) 313-320
78. Malkin D., Li F.P., Strong L.C., Fraumeni Jr. J.F., Nelson C.E., Kim D.H., Kassel J., Gryka M.A., Bischoff F.Z., Tainsky M.A., et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250 (1990) 1233-1238
79. Greenblatt M.S., Bennett W.P., Hollstein M., and Harris C.C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54 (1994) 4855-4878
80. Borresen-Dale A.L. TP53 and breast cancer. Hum. Mutat. 21 (2003) 292-300
81. Soussi T. The p53 tumor suppressor gene: from molecular biology to clinical investigation. Ann. NY Acad. Sci. 910 (2000) 121-137 discussion 137-129
82. de Cremoux P., Salomon A.V., Liva S., Dendale R., Bouchind'homme B., Martin E., Sastre-Garau X., Magdelenat H., Fourquet A., and Soussi T. p53 mutation as a genetic trait of typical medullary breast carcinoma. J. Natl. Cancer Inst. 91 (1999) 641-643
83. Sengupta S., and Harris C.C. p53: traffic cop at the crossroads of DNA repair and recombination. Nat. Rev. Mol. Cell Biol. 6 (2005) 44-55
84. Yoon D., Wang Y., Stapleford K., Wiesmuller L., and Chen J. P53 inhibits strand exchange and replication fork regression promoted by human Rad51. J. Mol. Biol. 336 (2004) 639-654
85. Susse S., Janz C., Janus F., Deppert W., and Wiesmuller L. Role of heteroduplex joints in the functional interactions between human Rad51 and wild-type p53. Oncogene 19 (2000) 4500-4512
86. Eyfjord J.E., Thorlacius S., Steinarsdottir M., Valgardsdottir R., Ogmundsdottir H.M., and Anamthawat-Jonsson K. p53 abnormalities and genomic instability in primary human breast carcinomas. Cancer Res. 55 (1995) 646-651
87. Blackburn A.C., McLary S.C., Naeem R., Luszcz J., Stockton D.W., Donehower L.A., Mohammed M., Mailhes J.B., Soferr T., Naber S.P., Otis C.N., and Jerry D.J. Loss of heterozygosity occurs via mitotic recombination in Trp53+/- mice and associates with mammary tumor susceptibility of the BALB/c strain. Cancer Res. 64 (2004) 5140-5147
88. Zhuang J., Zhang J., Willers H., Wang H., Chung J.H., van Gent D.C., Hallahan D.E., Powell S.N., and Xia F. Checkpoint kinase 2-mediated phosphorylation of BRCA1 regulates the fidelity of nonhomologous end-joining. Cancer Res. 66 (2006) 1401-1408
89. Wang H.C., Chou W.C., Shieh S.Y., and Shen C.Y. Ataxia telangiectasia mutated and checkpoint kinase 2 regulate BRCA1 to promote the fidelity of DNA end-joining. Cancer Res. 66 (2006) 1391-1400
90. Bell D.W., Varley J.M., Szydlo T.E., Kang D.H., Wahrer D.C., Shannon K.E., Lubratovich M., Verselis S.J., Isselbacher K.J., Fraumeni J.F., Birch J.M., Li F.P., Garber J.E., and Haber D.A. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 286 (1999) 2528-2531
91. Thompson D., and Easton D. The genetic epidemiology of breast cancer genes. J. Mammary Gland Biol. Neoplasia 9 (2004) 221-236
92. Varley J., and Haber D.A. Familial breast cancer and the hCHK2 1100delC mutation: assessing cancer risk. Breast Cancer Res. 5 (2003) 123-125
93. Meijers-Heijboer H., van den Ouweland A., Klijn J., Wasielewski M., de Snoo A., Oldenburg R., Hollestelle A., Houben M., Crepin E., van Veghel-Plandsoen M., Elstrodt F., van Duijn C., Bartels C., Meijers C., Schutte M., McGuffog L., Thompson D., Easton D., Sodha N., Seal S., Barfoot R., Mangion J., Chang-Claude J., Eccles D., Eeles R., Evans D.G., Houlston R., Murday V., Narod S., Peretz T., Peto J., Phelan C., Zhang H.X., Szabo C., Devilee P., Goldgar D., Futreal P.A., Nathanson K.L., Weber B., Rahman N., and Stratton M.R. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat. Genet. 31 (2002) 55-59
94. Sodha N., Bullock S., Taylor R., Mitchell G., Guertl-Lackner B., Williams R.D., Bevan S., Bishop K., McGuire S., Houlston R.S., and Eeles R.A. CHEK2 variants in susceptibility to breast cancer and evidence of retention of the wild type allele in tumours. Br. J. Cancer 87 (2002) 1445-1448
95. Sodha N., Wilson C., Bullock S.L., Phillimore H., Houlston R.S., and Eeles R.A. Analysis of familial male breast cancer for germline mutations in CHEK2. Cancer Lett. 215 (2004) 187-189
96. Vahteristo P., Bartkova J., Eerola H., Syrjakoski K., Ojala S., Kilpivaara O., Tamminen A., Kononen J., Aittomaki K., Heikkila P., Holli K., Blomqvist C., Bartek J., Kallioniemi O.P., and Nevanlinna H. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am. J. Hum. Genet. 71 (2002) 432-438
97. Johnson N., Fletcher O., Naceur-Lombardelli C., dos Santos Silva I., Ashworth A., and Peto J. Interaction between CHEK2*1100delC and other low-penetrance breast-cancer susceptibility genes: a familial study. Lancet 366 (2005) 1554-1557
98. Bellosillo B., Tusquets I., Longaron R., Perez-Lezaun A., Bellet M., Fabregat X., Serrano S., and Sole F. Absence of CHEK2 mutations in Spanish families with hereditary breast cancer. Cancer Genet. Cytogenet. 161 (2005) 93-95
99. Kleibl Z., Novotny J., Bezdickova D., Malik R., Kleiblova P., Foretova L., Petruzelka L., Ilencikova D., Cinek P., and Pohlreich P. The CHEK2 c.1100delC germline mutation rarely contributes to breast cancer development in the Czech Republic. Breast Cancer Res. Treat. 90 (2005) 165-167
100. Jekimovs C.R., Chen X., Arnold J., Gatei M., Richard D.J., Spurdle A.B., Khanna K.K., and Chenevix-Trench G. Low frequency of CHEK2 1100delC allele in Australian multiple-case breast cancer families: functional analysis in heterozygous individuals. Br. J. Cancer 92 (2005) 784-790
101. Friedrichsen D.M., Malone K.E., Doody D.R., Daling J.R., and Ostrander E.A. Frequency of CHEK2 mutations in a population based, case-control study of breast cancer in young women. Breast Cancer Res. 6 (2004) R629-R635
102. Rashid M.U., Jakubowska A., Justenhoven C., Harth V., Pesch B., Baisch C., Pierl C.B., Bruning T., Ko Y., Benner A., Wichmann H.E., Brauch H., and Hamann U. German populations with infrequent CHEK2*1100delC and minor associations with early-onset and familial breast cancer. Eur. J. Cancer 41 (2005) 2896-2903
103. Caligo M.A., Agata S., Aceto G., Crucianelli R., Manoukian S., Peissel B., Scaini M.C., Sensi E., Veschi S., Cama A., Radice P., Viel A., D'Andrea E., and Montagna M. The CHEK2 c.1100delC mutation plays an irrelevant role in breast cancer predisposition in Italy. Hum. Mutat. 24 (2004) 100-101
104. Bogdanova N., Enssen-Dubrowinskaja N., Feshchenko S., Lazjuk G.I., Rogov Y.I., Dammann O., Bremer M., Karstens J.H., Sohn C., and Dork T. Association of two mutations in the CHEK2 gene with breast cancer. Int. J. Cancer 116 (2005) 263-266
105. Huzarski T., Cybulski C., Domagala W., Gronwald J., Byrski T., Szwiec M., Woyke S., Narod S.A., and Lubinski J. Pathology of breast cancer in women with constitutional CHEK2 mutations. Breast Cancer Res. Treat. 90 (2005) 187-189
106. Kilpivaara O., Vahteristo P., Falck J., Syrjakoski K., Eerola H., Easton D., Bartkova J., Lukas J., Heikkila P., Aittomaki K., Holli K., Blomqvist C., Kallioniemi O.P., Bartek J., and Nevanlinna H. CHEK2 variant I157T may be associated with increased breast cancer risk. Int. J. Cancer 111 (2004) 543-547
107. Einarsdottir K., Humphreys K., Bonnard C., Palmgren J., Iles M.M., Sjolander A., Li Y., Chia K.S., Liu E.T., Hall P., Liu J., and Wedren S. Linkage disequilibrium mapping of CHEK2: common variation and breast cancer risk. PLoS Med. 3 (2006) e168
108. Walsh T., Casadei S., Coats K.H., Swisher E., Stray S.M., Higgins J., Roach K.C., Mandell J., Lee M.K., Ciernikova S., Foretova L., Soucek P., and King M.C. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 295 (2006) 1379-1388
109. Goode E.L., Ulrich C.M., and Potter J.D. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol. Biomarkers Prev. 11 (2002) 1513-1530
110. Han J., Hankinson S.E., Ranu H., De Vivo I., and Hunter D.J. Polymorphisms in DNA double-strand break repair genes and breast cancer risk in the Nurses' Health Study. Carcinogenesis 25 (2004) 189-195
111. Smith T.R., Levine E.A., Perrier N.D., Miller M.S., Freimanis R.I., Lohman K., Case L.D., Xu J., Mohrenweiser H.W., and Hu J.J. DNA-repair genetic polymorphisms and breast cancer risk. Cancer Epidemiol. Biomarkers Prev. 12 (2003) 1200-1204
112. Fu Y.P., Yu J.C., Cheng T.C., Lou M.A., Hsu G.C., Wu C.Y., Chen S.T., Wu H.S., Wu P.E., and Shen C.Y. Breast cancer risk associated with genotypic polymorphism of the nonhomologous end-joining genes: a multigenic study on cancer susceptibility. Cancer Res. 63 (2003) 2440-2446
113. Thompson L.H., and Schild D. Homologous recombinational repair of DNA ensures mammalian chromosome stability. Mutat. Res. 477 (2001) 131-153
114. Katoh M. Evolutionary recombination hotspot around GSDML-GSDM locus is closely linked to the oncogenomic recombination hotspot around the PPP1R1B-ERBB2-GRB7 amplicon. Int. J. Oncol. 24 (2004) 757-763
115. Venkitaraman A.R. Medicine: aborting the birth of cancer. Nature 434 (2005) 829-830
116. Jones P.A., and Baylin S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3 (2002) 415-428
117. Thompson M.E., Jensen R.A., Obermiller P.S., Page D.L., and Holt J.T. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat. Genet. 9 (1995) 444-450
118. Wilson C.A., Ramos L., Villasenor M.R., Anders K.H., Press M.F., Clarke K., Karlan B., Chen J.J., Scully R., Livingston D., Zuch R.H., Kanter M.H., Cohen S., Calzone F.J., and Slamon D.J. Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nat. Genet. 21 (1999) 236-240
119. Mueller C.R., and Roskelley C.D. Regulation of BRCA1 expression and its relationship to sporadic breast cancer. Breast Cancer Res. 5 (2003) 45-52
120. Rice J.C., Ozcelik H., Maxeiner P., Andrulis I., and Futscher B.W. Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens. Carcinogenesis 21 (2000) 1761-1765
121. Angele S., and Hall J. The ATM gene and breast cancer: is it really a risk factor?. Mutat. Res. 462 (2000) 167-178
122. Kim W.J., Vo Q.N., Shrivastav M., Lataxes T.A., and Brown K.D. Aberrant methylation of the ATM promoter correlates with increased radiosensitivity in a human colorectal tumor cell line. Oncogene 21 (2002) 3864-3871
123. Sullivan A., Yuille M., Repellin C., Reddy A., Reelfs O., Bell A., Dunne B., Gusterson B.A., Osin P., Farrell P.J., Yulug I., Evans A., Ozcelik T., Gasco M., and Crook T. Concomitant inactivation of p53 and Chk2 in breast cancer. Oncogene 21 (2002) 1316-1324
124. Raman V., Martensen S.A., Reisman D., Evron E., Odenwald W.F., Jaffee E., Marks J., and Sukumar S. Compromised HOXA5 function can limit p53 expression in human breast tumours. Nature 405 (2000) 974-978
125. Gonzalez R., Silva J.M., Dominguez G., Garcia J.M., Martinez G., Vargas J., Provencio M., Espana P., and Bonilla F. Detection of loss of heterozygosity at RAD51, RAD52, RAD54 and BRCA1 and BRCA2 loci in breast cancer: pathological correlations. Br. J. Cancer 81 (1999) 503-509
126. Staff S., Isola J.J., Johannsson O., Borg A., and Tanner M.M. Frequent somatic loss of BRCA1 in breast tumours from BRCA2 germ-line mutation carriers and vice versa. Br. J. Cancer 85 (2001) 1201-1205
127. Johnson S.M., Shaw J.A., and Walker R.A. Sporadic breast cancer in young women: prevalence of loss of heterozygosity at p53, BRCA1 and BRCA2. Int. J. Cancer 98 (2002) 205-209
128. Ding S.L., Sheu L.F., Yu J.C., Yang T.L., Chen B.F., Leu F.J., and Shen C.Y. Abnormality of the DNA double-strand-break checkpoint/repair genes, ATM, BRCA1 and TP53, in breast cancer is related to tumour grade. Br. J. Cancer 90 (2004) 1995-2001
129. Kwiatkowska E., Teresiak M., Breborowicz D., and Mackiewicz A. Somatic mutations in the BRCA2 gene and high frequency of allelic loss of BRCA2 in sporadic male breast cancer. Int. J. Cancer 98 (2002) 943-945
130. Maacke H., Jost K., Opitz S., Miska S., Yuan Y., Hasselbach L., Luttges J., Kalthoff H., and Sturzbecher H.W. DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma. Oncogene 19 (2000) 2791-2795
131. Hughes-Davies L., Huntsman D., Ruas M., Fuks F., Bye J., Chin S.F., Milner J., Brown L.A., Hsu F., Gilks B., Nielsen T., Schulzer M., Chia S., Ragaz J., Cahn A., Linger L., Ozdag H., Cattaneo E., Jordanova E.S., Schuuring E., Yu D.S., Venkitaraman A., Ponder B., Doherty A., Aparicio S., Bentley D., Theillet C., Ponting C.P., Caldas C., and Kouzarides T. EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell 115 (2003) 523-535
132. Dong Y., Hakimi M.A., Chen X., Kumaraswamy E., Cooch N.S., Godwin A.K., and Shiekhattar R. Regulation of BRCC, a holoenzyme complex containing BRCA1 and BRCA2, by a signalosome-like subunit and its role in DNA repair. Mol. Cell 12 (2003) 1087-1099
133. Sinilnikova O.M., Ginolhac S.M., Magnard C., Leone M., Anczukow O., Hughes D., Moreau K., Thompson D., Coutanson C., Hall J., Romestaing P., Gerard J.P., Bonadona V., Lasset C., Goldgar D.E., Joulin V., Venezia N.D., and Lenoir G.M. Acetyl-CoA carboxylase alpha gene and breast cancer susceptibility. Carcinogenesis 25 (2004) 2417-2424
134. Wu J.Y., Vlastos A.T., Pelte M.F., Caligo M.A., Bianco A., Krause K.H., Laurent G.J., and Irminger-Finger I. Aberrant expression of BARD1 in breast and ovarian cancers with poor prognosis. Int. J. Cancer 118 (2006) 1215-1226
135. Meng Z.H., Ben Y., Li Z., Chew K., Ljung B.M., Lagios M.D., and Dairkee S.H. Aberrations of breast cancer susceptibility genes occur early in sporadic breast tumors and in acquisition of breast epithelial immortalization. Genes. Chromosomes Cancer 41 (2004) 214-222
136. Vilenchik M.M., and Knudson A.G. Endogenous DNA double-strand breaks: production, fidelity of repair, and induction of cancer. Proc. Natl. Acad. Sci. USA 100 (2003) 12871-12876
137. Ramos J.M., Ruiz A., Colen R., Lopez I.D., Grossman L., and Matta J.L. DNA repair and breast carcinoma susceptibility in women. Cancer 100 (2004) 1352-1357
138. Wu K., Hinson S.R., Ohashi A., Farrugia D., Wendt P., Tavtigian S.V., Deffenbaugh A., Goldgar D., and Couch F.J. Functional evaluation and cancer risk assessment of BRCA2 unclassified variants. Cancer Res. 65 (2005) 417-426
139. Bryant H.E., Schultz N., Thomas H.D., Parker K.M., Flower D., Lopez E., Kyle S., Meuth M., Curtin N.J., and Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434 (2005) 913-917
140. Farmer H., McCabe N., Lord C.J., Tutt A.N., Johnson D.A., Richardson T.B., Santarosa M., Dillon K.J., Hickson I., Knights C., Martin N.M., Jackson S.P., Smith G.C., and Ashworth A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434 (2005) 917-921